Rytary
Total Payments
$730,192
Transactions
58
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $730,192 | 58 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $730,192 | 58 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS | Amneal Pharmaceuticals LLC | $603,877 | 0 |
| AN OPEN-LABEL EXTENSION STUDY OF THE SAFETY AND CLINICAL UTILITY OF IPX203 IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS | Amneal Pharmaceuticals LLC | $126,314 | 0 |
Top Doctors Receiving Payments for Rytary
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cleveland, OH | $730,192 | 58 |
Ad
Manufacturing Companies
- Amneal Pharmaceuticals LLC $730,192
Product Information
- Type Drug
- Total Payments $730,192
- Total Doctors 0
- Transactions 58
About Rytary
Rytary is a drug associated with $730,192 in payments to 0 healthcare providers, recorded across 58 transactions in the CMS Open Payments database. The primary manufacturer is Amneal Pharmaceuticals LLC.
Payment data is available from 2020 to 2020. In 2020, $730,192 was paid across 58 transactions to 0 doctors.
The most common payment nature for Rytary is "Unspecified" ($730,192, 100.0% of total).
Rytary is associated with 2 research studies, including "A RANDOMIZED CONTROLLED STUDY TO COMPARE THE SAFETY AND EFFICACY OF IPX203 WITH IMMEDIATE-RELEASE CARBIDOPA-LEVODOPA IN PARKINSON'S DISEASE PATIENTS WITH MOTOR FLUCTUATIONS" ($603,877).